TherapeuticsMD (TXMD) Cash from Financing Activities (2011 - 2023)

TherapeuticsMD's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $2.0 million for Q4 2023.

• Quarterly Cash from Financing Activities rose 101.79% year-over-year to $2.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$108.2 million (up 54.0% YoY) and the FY2023 annual result came in at $3.2 million, up 101.34% from the prior year.
• Cash from Financing Activities was $2.0 million for Q4 2023 at TherapeuticsMD, up from -$1000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $111.7 million in Q2 2019 and bottomed at -$120.0 million in Q2 2022.
• A 5-year average of $9.2 million and a median of $890500.0 in 2021 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2020 — Cash from Financing Activities jumped 48669.82% — and 2022, when it slumped 28137.38%.
• TherapeuticsMD's Cash from Financing Activities stood at $77.0 million in 2019, then plunged by 58.84% to $31.7 million in 2020, then sank by 95.73% to $1.4 million in 2021, then sank by 8373.84% to -$111.9 million in 2022, then surged by 101.79% to $2.0 million in 2023.
• Business Quant data shows TXMD's Cash from Financing Activities at $2.0 million in Q4 2023, -$1000.0 in Q3 2023, and -$111.9 million in Q4 2022.